01558 HEC CJ PHARM
- 12.160
- -1.000-7.60%
HEC CJ PHARM News
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Guangdong Dongyangguang Pharmaceutical plans to absorb and merge Dongyangguang Changjiang Pharmaceutical (01558) to resume trading on May 13
Dongyangguang Changjiang Pharmaceutical (01558) announced that the company's shares will be at 9:00 a.m. on May 13, 2024...
Dongyangguang Changjiang Pharmaceutical (01558.HK) was absorbed by Guangdong Dongyangyang Pharmaceutical at a premium of about 71.71% and resumed trading on the 13th
Gelonghui, May 10, 丨 Dongyangguang Changjiang Pharmaceutical (01558.HK) announced that on May 10, 2024, the offender Guangdong Dongyangyang Pharmaceutical Co., Ltd. has entered into a merger agreement with the company. According to this, the offeror and the company have agreed to implement the merger in accordance with the terms and conditions of the merger agreement. After the prerequisites and such conditions are met and the share exchange is completed, the company will be delisted. The offeror's H shares will be listed on the main board of the Stock Exchange by means of an introduction, and the company will be merged and absorbed by the offeror in accordance with the terms of the merger agreement, Chinese company law and other applicable Chinese laws. Shareholders in exchange will be entitled to receive from the offeror:
HEC CJ PHARM: JOINT ANNOUNCEMENT (1) PROPOSED PRE-CONDITIONAL PRIVATISATION OF YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. BY SUNSHINE LAKE PHARMA CO., LTD. BY WAY OF MERGER BY ABSORPTION OF YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LT...
Yichang HEC Still Negotiating Merger Deal With Sunshine Lake Pharma
Yichang HEC Changjiang Pharmaceutical (HKG:1558) provided an update about potentially merging its business with Sunshine Lake Pharma, saying the latter "is still exploring the proposal on the possible
Featured announcements | Zhonghai Real Estate's sales fell 30% year on year; Shangtang plans to build a joint venture to build a big data computing power platform
Guolian Securities: Major asset restructuring is still in the planning stage; Sunac China: cumulative contract sales in the first 4 months were 22.45 billion yuan, a year-on-year decrease of 39.86%.
Dongyangguang Changjiang Pharmaceutical (01558): Potential Offerers Are Still Exploring Possible Merger Plans
Dongyangguang Changjiang Pharmaceutical (01558) and potential offender Guangdong Dongyangguang Pharmaceutical Co., Ltd. jointly announced that it is likely to...
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Dongyangguang Changjiang Pharmaceutical (01558.HK): Proposed election of the fourth board of directors and supervisors of the Supervisory Board
Dongyangguang Changjiang Pharmaceutical (01558.HK) issued an announcement that the term of the third board of directors is about to expire. On May 6, 2024, the company held a board meeting to consider and approve the following candidates for directors of the fourth board of directors of the company. It can only be confirmed after approval by the company's shareholders at the upcoming 2023 annual general meeting of shareholders of the company:
東陽光長江藥業：年度報告 2023
Changes in Hong Kong stocks | Dongyangguang Changjiang Pharmaceutical (01558) is now up more than 3%, and the procurement price of insulin is more moderate. The company plans to win the bid for 5 products
Dongyangguang Changjiang Pharmaceutical (01558) is now up more than 3%. As of press release, it is up 3.15% to HK$12.46, with a turnover of HK$18.895 million.
Express News | Insulin collection continues at the procurement site: only 1 minute away from the highest price and the lowest price
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger With Sunshine Lake Pharma
Yichang Hec Changjiang Pharmaceutical Co (HKG:1558) and Sunshine Lake Pharma jointly said that they are looking into the possibilities of a merger, according to a Monday Hong Kong bourse. A definitive
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Dongyangguang Changjiang Pharmaceutical (01558.HK): The potential offender has not proposed a clear plan for the possible merger to the company
Dongyangguang Changjiang Pharmaceutical (01558.HK) issued an announcement. Guangdong Dongyangyang Pharmaceutical Co., Ltd. (potential offender) announced that the executive had granted a waiver to the potential offeror, in accordance with Rule 26.1 (a) (1) (1) of the Takeovers Code; and (2) the executive had granted the relief specified in Rule 23.1 to exempt potential offenders from making a combined cash payment or cash option, with an amount not less than the transfer consideration.
Featured announcements | BYD's automobile sales in March increased 46.06% year on year; COSCO Haineng's profit more than doubled last year
Ideal Auto delivered 28,984 new cars in March, up 39.2% year on year; NIO delivered 11,866 cars in March, up 14.3% year on year; Xiaopeng Motor delivered 9,026 new cars in March, up 99% month on month, up 29% year on year.
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps
Yichang Hec Changjiang Pharmaceutical's (HKG:1558) net profit attributable to equity holders surged to 1.99 billion yuan in 2023 from 76.6 million yuan in 2022, according to a filing made with the Hon
Analysis
Price Target
No Data
